Search Results
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification
The promise of luspatercept for the treatment of lower-risk MDS
Luspatercept for the treatment of patients with lower-risk MDS and ESA failure
Treatment algorithm for low-risk MDS
What Major Themes Define Recent Lower-Risk MDS Prognostication, Treatment?
The COMMANDS study: luspatercept versus epoetin alfa for ESA-naïve lower-risk MDS-associated anemia
Lower-risk MDS in 2021: luspatercept, imetelstat & roxadustat
Real-world treatment patterns of patients with low-risk MDS reinitiating ESAs
The current standard of care for patients with lower-risk MDS
MEDALIST: OS & risk of disease progression in patients with MDS treated with luspatercept
Managing adverse events with novel therapies in lower-risk MDS
The optimal treatment of lower risk MDS
